Private equity firm Carlyle Group is in exclusive discussions to purchase Baxter International’s kidney care spinoff, Vantive, in a deal valued at around $4bn including debt, according to reports by Reuters and the Wall Street Journal.
The report cites an unnamed source in revealing that the parties entered exclusive negotiations in late June, and an announcement over a deal could be made in the coming weeks.
Shares of Baxter International, based in Deerfield, Illinois, have risen by more than 4% since news of the potential deal broke.
In March, Baxter announced it was exploring the sale of its kidney care unit with select private equity investors. The decision came more than a year after Baxter revealed plans to separate the unit due to supply chain challenges and weak demand for dialysis operations. The company aims to complete the separation in the second half of the year.
Can’t stop reading? Read more
Oscar-winning Lion Forge secures $30m from HarbourView to expand IP portfolio
Oscar-winning Lion Forge secures $30m from HarbourView to expand IP portfolio HarbourView Equity...
Klarna set to price IPO above range as demand surges for $1.27bn listing
Klarna set to price IPO above range as demand surges for $1.27bn listing Klarna is preparing to...
Dragon’s Den star Touker Suleyman bids to rescue Claire’s UK stores
Dragon’s Den star Touker Suleyman bids to rescue Claire’s UK stores Touker Suleyman, investor and...